RenÃ© Rizzoli

List of Publications by Year
in descending order

308 papers	39,374 citations	3334 91 h-index	3034 188 g-index
341 all docs	341 docs citations	341 times ranked	29370 citing authors

#	Article	IF	Citations
1	Dairy products and bone health. Aging Clinical and Experimental Research, 2022, 34, 9-24.	2.9	29
2	Reference microarchitectural values measured by HR-pQCT in a Franco-Swiss cohort of young adult women. Osteoporosis International, 2022, 33, 703-709.	3.1	0
3	Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporosis International, 2022, , 1.	3.1	0
4	The global approach to rehabilitation following an osteoporotic fragility fracture: A review ofÂthe rehabilitation working group of the International Osteoporosis FoundationÂ(IOF) committee of scientific advisors. Osteoporosis International, 2022, 33, 527-540.	3.1	23
5	Acquisition of peak bone mass. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101616.	4.7	21
6	Attributes and definitions of locomotor capacity in older people: a World Health Organisation (WHO) locomotor capacity working group meeting report. Aging Clinical and Experimental Research, 2022, 34, 481-483.	2.9	14
7	Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clinical and Experimental Research, 2022, 34, 695-714.	2.9	33
8	Associations of Calcium Intake and Calcium from Various Sources with Blood Lipids in a Population of Older Women and Men with High Calcium Intake. Nutrients, 2022, 14, 1314.	4.1	6
9	Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative. Archives of Osteoporosis, 2022, 17, 5.	2.4	2
10	Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nature Reviews Endocrinology, 2022, 18, 366-384.	9.6	42
11	Update on the ESCEO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. Aging Clinical and Experimental Research, 2021, 33, 3-17.	2.9	46
12	DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemporary Clinical Trials, 2021, 100, 106124.	1.8	28
13	Vitamin D supplementation: upper limit for safety revisited?. Aging Clinical and Experimental Research, 2021, 33, 19-24.	2.9	62
14	In memory of Harry K Genant. Osteoporosis International, 2021, 32, 607-608.	3.1	0
15	Hormonal regulation of biomineralization. Nature Reviews Endocrinology, 2021, 17, 261-275.	9.6	50
16	How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture?. Osteoporosis International, 2021, 32, 1921-1935.	3.1	6
17	Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology, 2021, 28, 100361.	2.4	14
18	Nutritional intake and bone health. Lancet Diabetes and Endocrinology,the, 2021, 9, 606-621.	11.4	98

#	Article	IF	Citations
19	Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporosis International, 2020, 31, 1-12.	3.1	220
20	Impact of whole dairy matrix on musculoskeletal health and agingâ€“current knowledge and research gaps. Osteoporosis International, 2020, 31, 601-615.	3.1	46
21	Outcome Priorities for Older Persons With Sarcopenia. Journal of the American Medical Directors Association, 2020, 21, 267-271.e2.	2.5	13
22	Relationship between bone mineral content and bone turnover markers, sex hormones and calciotropic hormones in pre- and early pubertal children. Osteoporosis International, 2020, 31, 335-349.	3.1	3
23	Nutritional strategies for maintaining muscle mass and strength from middle age to later life: A narrative review. Maturitas, 2020, 132, 57-64.	2.4	69
24	A discrete-choice experiment to assess patientsâ€™ preferences for osteoarthritis treatment: An ESCEO working group. Seminars in Arthritis and Rheumatism, 2020, 50, 859-866.	3.4	7
25	Associations between age-related changes in bone microstructure and strength and dietary acid load in a cohort of community-dwelling, healthy men and postmenopausal women. American Journal of Clinical Nutrition, 2020, 112, 1120-1131.	4.7	9
26	Nutrition and bone disease. , 2020, , 523-533.		0
27	Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs, 2020, 80, 1537-1552.	10.9	40
28	FRAX and ethnicity. Osteoporosis International, 2020, 31, 2063-2067.	3.1	12
29	Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. JAMA - Journal of the American Medical Association, 2020, 324, 1855.	7.4	180
30	Are Probiotics the New Calcium and Vitamin D for Bone Health?. Current Osteoporosis Reports, 2020, 18, 273-284.	3.6	50
31	Determinants of Peak Bone Mass Acquisition. Contemporary Endocrinology, 2020, , 115-137.	0.1	2
32	Fracture Risk Following an Atypical Femoral Fracture. Journal of Bone and Mineral Research, 2020, 37, 87-94.	2.8	8
33	East meets West: current practices and policies in the management of musculoskeletal aging. Aging Clinical and Experimental Research, 2019, 31, 1351-1373.	2.9	32
34	Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporosis International, 2019, 30, 2155-2165.	3.1	69
35	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Research Reviews, 2019, 55, 100946.	10.9	103
36	Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis. Advances in Therapy, 2019, 36, 2811-2824.	2.9	60

#	Article	IF	Citations
37	Nutritional influence on bone: role of gut microbiota. Aging Clinical and Experimental Research, 2019, 31, 743-751.	2.9	43
38	Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Annals of Oncology, 2019, 30, 908-920.	1.2	47
39	Safety of Paracetamol in Osteoarthritis: What Does the Literature Say?. Drugs and Aging, 2019, 36, 7-14.	2.7	59
40	Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs and Aging, 2019, 36, 65-99.	2.7	70
41	Focal and Osteosclerotic Bone Diseases. Calcified Tissue International, 2019, 104, 481-482.	3.1	0
42	Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review. Calcified Tissue International, 2019, 105, 109-124.	3.1	51
43	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Seminars in Arthritis and Rheumatism, 2019, 49, 337-350.	3.4	392
44	Higher rates of osteoporosis treatment initiation and persistence in patients with newly diagnosed vertebral fracture when introduced in inpatients than later in outpatients. Osteoporosis International, 2019, 30, 1353-1362.	3.1	7
45	Assessment of Muscle Function and Physical Performance in Daily Clinical Practice. Calcified Tissue International, 2019, 105, 1-14.	3.1	295
46	Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcified Tissue International, 2019, 104, 235-238.	3.1	105
47	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. European Journal of Endocrinology, 2019, 180, P1-P22.	3.7	81
48	Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clinical and Experimental Research, 2019, 31, 15-17.	2.9	40
49	Hypercalcemia: Other Causes than Primary Hyperparathyroidism. , 2019, , 160-167.		0
50	Osteoporosis: Treatment Gaps and Health Economics. , 2019, , 288-295.		7
51	Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an expertsâ€™ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International, 2019, 30, 45-57.	3.1	67
52	Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing, 2019, 48, 16-31.	1.6	6,824
53	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2019, 30, 3-44.	3.1	1,020
54	Diet, Microbiota, and Bone Health. , 2019, , 143-168.		2

#	Article	IF	Citations
55	Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 34-43.	11.4	244
56	Prevention of Osteoporosis and Fragility Fractures. , 2019, , 31-42.		0
57	Microbiota and Bone Health: The Gut-Musculoskeletal Axis. Calcified Tissue International, 2018, 102, 385-386.	3.1	8
58	Quality of life assessment in musculo-skeletal health. Aging Clinical and Experimental Research, 2018, 30, 413-418.	2.9	144
59	Interaction between LRP5 and periostin gene polymorphisms on serum periostin levels and cortical bone microstructure. Osteoporosis International, 2018, 29, 339-346.	3.1	20
60	Evaluation of Radius Microstructure and Areal Bone Mineral Density Improves Fracture Prediction in Postmenopausal Women. Journal of Bone and Mineral Research, 2018, 33, 328-337.	2.8	81
61	Pro-inflammatory dietary pattern is associated with fractures in women: an eight-year longitudinal cohort study. Osteoporosis International, 2018, 29, 143-151.	3.1	28
62	Effects of Fermented Milk Products on Bone. Calcified Tissue International, 2018, 102, 489-500.	3.1	57
63	Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clinical and Experimental Research, 2018, 30, 111-117.	2.9	56
64	Postmenopausal osteoporosis: Assessment and management. Best Practice and Research in Clinical Endocrinology and Metabolism, 2018, 32, 739-757.	4.7	64
65	Bone management in hematologic stem cell transplant recipients. Osteoporosis International, 2018, 29, 2597-2610.	3.1	39
66	ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2949-2957.	3.6	131
67	Phosphate wasting disorders in adults. Osteoporosis International, 2018, 29, 2369-2387.	3.1	32
68	Fermented dairy products consumption is associated with attenuated cortical bone loss independently of total calcium, protein, and energy intakes in healthy postmenopausal women. Osteoporosis International, 2018, 29, 1771-1782.	3.1	46
69	Benefits and safety of dietary protein for bone healthâ€"an expert consensus paper endorsed by the European Society for Clinical and Economical Aspects of Osteopororosis, Osteoarthritis, and Musculoskeletal Diseases and by the International Osteoporosis Foundation. Osteoporosis International, 2018, 29, 1933-1948.	3.1	98
70	MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of vitamin D. European Journal of Endocrinology, 2018, 179, R239-R259.	3.7	53
71	Review of the guideline of the American College of Physicians on the treatment of osteoporosis. Osteoporosis International, 2018, 29, 1505-1510.	3.1	26
72	English translation and validation of the SarQoL^{Â®}, a quality of life questionnaire specific for sarcopenia. Age and Ageing, 2017, 46, 271-276.	1.6	40

#	Article	IF	Citations
73	Prepubertal Impact of Protein Intake and Physical Activity on Weight Bearing Peak Bone Mass and Strength in Males. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2449.	3.6	9
74	International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporosis International, 2017, 28, 767-774.	3.1	113
75	Peripheral skeleton bone strength is positively correlated with total and dairy protein intakes in healthy postmenopausal women. American Journal of Clinical Nutrition, 2017, 105, 513-525.	4.7	107
76	Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporosis International, 2017, 28, 1817-1833.	3.1	381
77	Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International, 2017, 28, 1507-1529.	3.1	160
78	Patientsâ€™ preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment. Rheumatology, 2017, 56, 1167-1176.	1.9	26
79	Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporosis International, 2017, 28, 2023-2034.	3.1	126
80	Validation of the SarQoLÂ®, a specific healthâ€related quality of life questionnaire for Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 238-244.	7.3	166
81	Vitamin D supplementation in the prevention and management of major chronic diseases not related to mineral homeostasis in adults: research for evidence and a scientific statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO). Endocrine, 2017, 56, 245-261.	2.3	52
82	Vitamin D status correction in Saudi Arabia: an expertsâ€™ consensus under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO). Archives of Osteoporosis, 2017, 12, 1.	2.4	72
83	Strontium ranelate stimulates trabecular bone formation in a rat tibial bone defect healing process. Osteoporosis International, 2017, 28, 3475-3487.	3.1	20
84	Global dietary calcium intake among adults: a systematic review. Osteoporosis International, 2017, 28, 3315-3324.	3.1	249
85	Towards a better management of glucocorticoid-induced osteoporosis?. Nature Reviews Rheumatology, 2017, 13, 635-636.	8.0	5
86	Reply to D Xie and Z Sheng. American Journal of Clinical Nutrition, 2017, 106, 322-323.	4.7	0
87	Serum Levels of a Cathepsin-K Generated Periostin Fragment Predict Incident Low-Trauma Fractures in Postmenopausal Women Independently of BMD and FRAX. Journal of Bone and Mineral Research, 2017, 32, 2232-2238.	2.8	21
88	The role of calcium supplementation in healthy musculoskeletal ageing. Osteoporosis International, 2017, 28, 447-462.	3.1	130
89	CAPTURE THE FRACTURE: INTEGRATED CARE PREVENTS THE DECREASE IN INTRINSIC CAPACITY IN ELDERLY SUBJECTS. Innovation in Aging, 2017, 1, 692-692.	0.1	2
90	Yogurt Consumption and Impact on Bone Health. , 2017, , 507-524.		1

#	Article	IF	Citations
91	IMPACT OF DIABETES ON THE PREVALENCE OF MALNUTRITION AND SARCOPENIA IN AGED HOSPITALIZED PATIENTS. Innovation in Aging, 2017, 1, 149-150.	0.1	0
92	The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 2017, 8, 75646-75663.	1.8	53
93	Low Lean Mass Predicts Incident Fractures Independently From FRAX: a Prospective Cohort Study of Recent Retirees. Journal of Bone and Mineral Research, 2016, 31, 2048-2056.	2.8	80
94	A comprehensive fracture prevention strategy in older adults: the European Union Geriatric Medicine Society (EUGMS) statement. Aging Clinical and Experimental Research, 2016, 28, 797-803.	2.9	75
95	Influence of a fermented protein-fortified dairy product on serum insulin-like growth factor-I in women with anorexia nervosa: A randomized controlled trial. Clinical Nutrition, 2016, 35, 1032-1038.	5.0	11
96	Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. European Geriatric Medicine, 2016, 7, 243-246.	2.8	90
97	A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement. European Geriatric Medicine, 2016, 7, 519-525.	2.8	12
98	Sarcopenia in daily practice: assessment and management. BMC Geriatrics, 2016, 16, 170.	2.7	468
99	Selective protein depletion impairs bone growth and causes liver fatty infiltration in female rats: prevention by Spirulina alga. Osteoporosis International, 2016, 27, 3365-3376.	3.1	8
100	Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Archives of Osteoporosis, 2016, 11, 37.	2.4	50
101	A comprehensive fracture prevention strategy in older adults: The European Union Geriatric Medicine Society (EUGMS) statement. Journal of Nutrition, Health and Aging, 2016, 20, 647-652.	3.3	65
102	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clinical and Experimental Research, 2016, 28, 1-16.	2.9	22
103	Occupation-dependent loading increases bone strength in men. Osteoporosis International, 2016, 27, 1169-1179.	3.1	6
104	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. Drugs and Aging, 2016, 33, 75-85.	2.7	116
105	Continuous treatment with odanacatib for up to 8Âyears in postmenopausal women with low bone mineral density: a phase 2 study. Osteoporosis International, 2016, 27, 2099-2107.	3.1	32
106	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
107	Effects of Dairy Products Consumption on Health: Benefits and Beliefsâ€"A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. Calcified Tissue International, 2016, 98, 1-17.	3.1	210
108	Additive Genetic Effects on Circulating Periostin Contribute to the Heritability of Bone Microstructure. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1014-E1021.	3.6	27

#	Article	IF	Citations
109	Life-course approach to nutrition. Osteoporosis International, 2015, 26, 2723-2742.	3.1	51
110	Nutrition and Sarcopenia. Journal of Clinical Densitometry, 2015, 18, 483-487.	1.2	16
111	The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Endocrine, 2015, 50, 12-26.	2.3	53
112	Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Current Medical Research and Opinion, 2015, 31, 1041-1045.	1.9	22
113	Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporosis International, 2015, 26, 2793-2802.	3.1	207
114	Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women. Osteoporosis International, 2015, 26, 383-393.	3.1	13
115	Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis. Climacteric, 2015, 18, 805-812.	2.4	19
116	The position of strontium ranelate in todayâ€™s management of osteoporosis. Osteoporosis International, 2015, 26, 1667-1671.	3.1	81
117	Prior ankle fractures in postmenopausal women are associated with low areal bone mineral density and bone microstructure alterations. Osteoporosis International, 2015, 26, 2147-2155.	3.1	40
118	Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age and Ageing, 2015, 44, 960-966.	1.6	89
119	Glucocorticoid-induced osteoporosis: who to treat with what agent?. Nature Reviews Rheumatology, 2015, 11, 98-109.	8.0	129
120	Effects of vitamin D in the elderly population: current status and perspectives. Archives of Public Health, 2014, 72, 32.	2.4	56
121	Nutrition and Bone Health in Women after the Menopause. Women's Health, 2014, 10, 599-608.	1.5	58
122	Systemic Treatment with Strontium Ranelate Accelerates the Filling of a Bone Defect and Improves the Material Level Properties of the Healing Bone. BioMed Research International, 2014, 2014, 1-10.	1.9	23
123	A Low Protein Diet Alters Bone Material Level Properties and the Response toIn VitroRepeated Mechanical Loading. BioMed Research International, 2014, 2014, 1-6.	1.9	2
124	Dairy products, yogurts, and bone health. American Journal of Clinical Nutrition, 2014, 99, 1256S-1262S.	4.7	168
125	Nutritional aspects of bone health. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 795-808.	4.7	76
126	Nutrition and bone health: turning knowledge and beliefs into healthy behaviour. Current Medical Research and Opinion, 2014, 30, 131-141.	1.9	30

#	Article	IF	Citations
127	Sarcopenia: burden and challenges for public health. Archives of Public Health, 2014, 72, 45.	2.4	317
128	High Bone Density in Adolescents With Obesity Is Related to Fat Mass and Serum Leptin Concentrations. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 723-728.	1.8	28
129	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 253-263.	3.4	414
130	Tracking of Environmental Determinants of Bone Structure and Strength Development in Healthy Boys: An Eight-Year Follow Up Study on the Positive Interaction Between Physical Activity and Protein Intake From Prepuberty to Mid-Late Adolescence. Journal of Bone and Mineral Research, 2014, 29, 2182-2192.	2.8	27
131	Correction of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients. European Journal of Endocrinology, 2014, 170, 441-450.	3.7	8
132	Long-Term Exercise in Older Adults: 4-Year Outcomes of Music-Based Multitask Training. Calcified Tissue International, 2014, 95, 393-404.	3.1	30
133	Goal-directed treatment of osteoporosis in Europe. Osteoporosis International, 2014, 25, 2533-2543.	3.1	61
134	Low Calcium-Phosphate Intakes Modulate the Low-Protein Diet-Related Effect on Peak Bone Mass Acquisition: A Hormonal and Bone Strength Determinants Study in Female Growing Rats. Endocrinology, 2014, 155, 4305-4315.	2.8	11
135	The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: A consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas, 2014, 79, 122-132.	2.4	213
136	Management of osteoporosis of the oldest old. Osteoporosis International, 2014, 25, 2507-2529.	3.1	71
137	Epidemiology and economic burden of osteoporosis in Switzerland. Archives of Osteoporosis, 2014, 9, 187.	2.4	81
138	Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporosis International, 2013, 24, 1555-1566.	3.1	236
139	Tools in the Assessment of Sarcopenia. Calcified Tissue International, 2013, 93, 201-210.	3.1	197
140	Quality of Life in Sarcopenia and Frailty. Calcified Tissue International, 2013, 93, 101-120.	3.1	310
141	In vitro bone exposure to strontium improves bone material level properties. Acta Biomaterialia, 2013, 9, 7005-7013.	8.3	24
142	SCOPE: a scorecard for osteoporosis in Europe. Archives of Osteoporosis, 2013, 8, 144.	2.4	125
143	Cancer-associated bone disease. Osteoporosis International, 2013, 24, 2929-2953.	3.1	113
144	Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Current Medical Research and Opinion, 2013, 29, 305-313.	1.9	266

#	Article	IF	Citations
145	Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporosis International, 2013, 24, 139-150.	3.1	38
146	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2013, 24, 23-57.	3.1	1,560
147	3-year follow-up results of bone mineral content and density after a school-based physical activity randomized intervention trial. Bone, 2013, 55, 16-22.	2.9	27
148	Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius. Bone, 2013, 55, 377-383.	2.9	42
149	Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3873-3883.	3.6	85
150	Selective Determinants of Low Bone Mineral Mass in Adult Women with Anorexia Nervosa. International Journal of Endocrinology, 2013, 2013, 1-9.	1.5	16
151	Strontium Ranelate in the Prevention of Osteoporotic Fractures. , 2013, , 1935-1947.		0
152	Are Bisphosphonates Associated With an Increased Risk of Atypical Femoral Fractures as a Class?â€"Reply. JAMA Internal Medicine, 2013, 173, 79.	5.1	0
153	A critical pathway for the management of elderly inpatients with malnutrition: effects on serum insulin-like growth factor-I. European Journal of Clinical Nutrition, 2013, 67, 1175-1181.	2.9	7
154	Fractures in Healthy Females Followed from Childhood to Early Adulthood Are Associated with Later Menarcheal Age and with Impaired Bone Microstructure at Peak Bone Mass. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4174-4181.	3.6	63
155	Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfectaâ€"a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 548-550.	3.3	30
156	Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine, 2012, 367, 1714-1723.	27.0	285
157	Cost-effective intervention thresholds against osteoporotic fractures based on FRAXÂ® in Switzerland. Osteoporosis International, 2012, 23, 2579-2589.	3.1	66
158	Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteoporosis International, 2012, 23, 2567-2576.	3.1	83
159	Prevalence of vertebral fracture in oldest old nursing home residents. Osteoporosis International, 2012, 23, 2601-2606.	3.1	25
160	Antidepressant medications and osteoporosis. Bone, 2012, 51, 606-613.	2.9	144
161	Increasing Occurrence of Atypical Femoral Fractures Associated With Bisphosphonate Use. Archives of Internal Medicine, 2012, 172, 930-6.	3.8	187
162	Management of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 2012, 91, 225-243.	3.1	77

#	Article	IF	Citations
163	Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Current Medical Research and Opinion, 2012, 28, 475-491.	1.9	39
164	Frailty and sarcopenia: definitions and outcome parameters. Osteoporosis International, 2012, 23, 1839-1848.	3.1	258
165	Implications for Fracture Healing of Current and New Osteoporosis Treatments: An ESCEO Consensus Paper. Calcified Tissue International, 2012, 90, 343-353.	3.1	111
166	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2012, 27, 211-218.	2.8	124
167	Assessment of health claims in the field of bone: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporosis International, 2012, 23, 193-199.	3.1	6
168	Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Osteoporosis International, 2012, 23, 305-315.	3.1	76
169	A reappraisal of generic bisphosphonates in osteoporosis. Osteoporosis International, 2012, 23, 213-221.	3.1	62
170	Official Positions for FRAXÂ® Clinical Regarding International Differences. Journal of Clinical Densitometry, 2011, 14, 240-262.	1.2	84
171	Adverse drug reactions to osteoporosis treatments. Expert Review of Clinical Pharmacology, 2011, 4, 593-604.	3.1	37
172	Effect of a general school-based physical activity intervention on bone mineral content and density: A cluster-randomized controlled trial. Bone, 2011, 48, 792-797.	2.9	70
173	Selective osteoblast overexpression of IGF-I in mice prevents low protein-induced deterioration of bone strength and material level properties. Bone, 2011, 49, 1073-1079.	2.9	18
174	Socioeconomic and living conditions are determinants of hip fracture incidence and age occurrence among community-dwelling elderly. Osteoporosis International, 2011, 22, 647-653.	3.1	43
175	Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International, 2011, 22, 373-390.	3.1	220
176	Interpretation and use of FRAX in clinical practice. Osteoporosis International, 2011, 22, 2395-2411.	3.1	450
177	Adverse Reactions and Drugâ€“Drug Interactions in the Management of Women with Postmenopausal Osteoporosis. Calcified Tissue International, 2011, 89, 91-104.	3.1	170
178	Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect. Journal of Bone and Mineral Research, 2011, 26, 242-251.	2.8	220
179	Calcitropic Hormones and IGF-I Are Influenced by Dietary Protein. Endocrinology, 2011, 152, 1839-1847.	2.8	25
180	Effect of Music-Based Multitask Training on Gait, Balance, and Fall Risk in Elderly People. Archives of Internal Medicine, 2011, 171, 525-33.	3.8	198

#	Article	IF	Citations
181	Fractures during Childhood and Adolescence in Healthy Boys: Relation with Bone Mass, Microstructure, and Strength. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3134-3142.	3.6	69
182	Bisphosphonates for post-menopausal osteoporosis: are they all the same?. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 281-300.	0.5	50
183	Indications to teriparatide treatment in patients with osteoporosis. Swiss Medical Weekly, 2011, 141, w13297.	1.6	9
184	Protein Undernutrition-Induced Bone Loss Is Associated with Decreased IGF-I Levels and Estrogen Deficiency. Journal of Bone and Mineral Research, 2010, 15, 683-690.	2.8	130
185	FRAXÂ® assessment of osteoporotic fracture probability in Switzerland. Osteoporosis International, 2010, 21, 381-389.	3.1	106
186	PTH improves titanium implant fixation more than pamidronate or renutrition in osteopenic rats chronically fed a low protein diet. Osteoporosis International, 2010, 21, 957-967.	3.1	30
187	Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporosis International, 2010, 21, 723-732.	3.1	61
188	Microarchitecture in focus. Osteoporosis International, 2010, 21, 403-406.	3.1	6
189	Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatology International, 2010, 30, 1341-1348.	3.0	66
190	The gaps between patient and physician understanding of the emotional and physical impact of osteoporosis. Archives of Osteoporosis, 2010, 5, 145-153.	2.4	10
191	Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture. Clinical Nutrition, 2010, 29, 78-83.	5.0	48
192	Denosumab. Nature Reviews Drug Discovery, 2010, 9, 591-592.	46.4	42
193	Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 3-16.	2.7	15
194	Management of the oldest old with osteoporosis. European Geriatric Medicine, 2010, 1, 15-21.	2.8	7
195	Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone, 2010, 46, 294-305.	2.9	510
196	Strontium ranelate improves implant osseointegration. Bone, 2010, 46, 1436-1441.	2.9	124
197	Administration of growth hormone in selectively protein-deprived rats decreases BMD and bone strength. Bone, 2010, 46, 1574-1581.	2.9	8
198	Management of osteoporosis in the elderly. Current Medical Research and Opinion, 2009, 25, 2373-2387.	1.9	69

#	Article	IF	Citations
199	Zinc increases the effects of essential amino acids-whey protein supplements in frail elderly. Journal of Nutrition, Health and Aging, 2009, 13, 491-497.	3.3	37
200	Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporosis International, 2009, 20, 1131-1140.	3.1	171
201	Deleterious Effect of Late Menarche on Distal Tibia Microstructure in Healthy 20-Year-Old and Premenopausal Middle-Aged Women. Journal of Bone and Mineral Research, 2009, 24, 144-152.	2.8	69
202	Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?. Bone, 2009, 45, 843-852.	2.9	189
203	High-Protein Intake Enhances the Positive Impact of Physical Activity on BMC in Prepubertal Boys. Journal of Bone and Mineral Research, 2008, 23, 131-142.	2.8	86
204	European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International, 2008, 19, 399-428.	3.1	792
205	Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporosis International, 2008, 19, 1741-1747.	3.1	43
206	Weight-bearing bones are more sensitive to physical exercise in boys than in girls during pre- and early puberty: a cross-sectional study. Osteoporosis International, 2008, 19, 1749-1758.	3.1	63
207	Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporosis International, 2008, 19, 1247-1250.	3.1	26
208	A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women â€" Study protocol. Trials, 2008, 9, 19.	1.6	3
209	Nutrition: its role in bone health. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 813-829.	4.7	91
210	The role of calcium and vitamin D in the management of osteoporosis. Bone, 2008, 42, 246-249.	2.9	124
211	Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone, 2008, 42, 841-847.	2.9	189
212	Dietary Protein and Bone Health: Roles of Amino Acidâ€"Sensing Receptors in the Control of Calcium Metabolism and Bone Homeostasis. Annual Review of Nutrition, 2008, 28, 131-155.	10.1	91
213	Post-fracture management of patients with hip fracture: a perspective. Current Medical Research and Opinion, 2008, 24, 2841-2851.	1.9	31
214	Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology, 2008, 19, 420-432.	1.2	410
215	Influence of Age at Menarche on Forearm Bone Microstructure in Healthy Young Women. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2594-2601.	3.6	71
216	Osteoporosis: non-hormonal treatment. Climacteric, 2007, 10, 74-78.	2.4	9

#	Article	IF	Citations
217	Gene-Environment Interactions in the Skeletal Response to Nutrition and Exercise during Growth. , 2007, 51, 64-80.		111
218	International society of geriatric oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. European Journal of Cancer, 2007, 43, 852-858.	2.8	83
219	Incidence of hip fracture over a 10-year period (1991â€“2000): Reversal of a secular trend. Bone, 2007, 40, 1284-1289.	2.9	164
220	Long-term strategy in the management of postmenopausal osteoporosis. Joint Bone Spine, 2007, 74, 540-543.	1.6	7
221	Strontium Ranelate Treatment Improves Trabecular and Cortical Intrinsic Bone Tissue Quality, a Determinant of Bone Strength. Journal of Bone and Mineral Research, 2007, 22, 1419-1425.	2.8	147
222	Defective Implant Osseointegration Under Protein Undernutrition: Prevention by PTH or Pamidronate. Journal of Bone and Mineral Research, 2007, 22, 1526-1533.	2.8	32
223	Determinants of peak bone mass. Annales D'Endocrinologie, 2006, 67, 114-115.	1.4	11
224	Physiology of Calcium and Phosphate Homeostases. , 2006, , 345-360.		22
225	Physiology of Calcium and Phosphate Homeostases. , 2006, , 345-360.		8
226	Long-term Outcome of Weekly Bisphosphonates. Clinical Orthopaedics and Related Research, 2006, 443, 61-65.	1.5	14
227	Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study. International Journal of Clinical Practice, 2006, 60, 1013-1019.	1.7	54
228	Targeted education improves the very low recognition of vertebral fractures and osteoporosis management by general internists. Osteoporosis International, 2006, 17, 965-970.	3.1	25
229	Long-Term Use of Bisphosphonates in Osteoporosis. Women's Health, 2006, 2, 309-315.	1.5	2
230	Pamidronate Prevents Bone Loss and Decreased Bone Strength in Adult Female and Male Rats Fed an Isocaloric Low-Protein Diet. Journal of Bone and Mineral Research, 2005, 20, 1365-1371.	2.8	16
231	Low Protein Intake Is Associated With Impaired Titanium Implant Osseointegration. Journal of Bone and Mineral Research, 2005, 21, 258-264.	2.8	23
232	Childhood Fractures Are Associated With Decreased Bone Mass Gain During Puberty: An Early Marker of Persistent Bone Fragility?. Journal of Bone and Mineral Research, 2005, 21, 501-507.	2.8	147
233	A rapid self-administered food frequency questionnaire for the evaluation of dietary protein intake. Clinical Nutrition, 2005, 24, 768-774.	5.0	50
234	Fibroblast Growth Factor-23 Relationship to Dietary Phosphate and Renal Phosphate Handling in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1519-1524.	3.6	481

#	Article	IF	Citations
235	Interaction between Calcium Intake and Menarcheal Age on Bone Mass Gain: An Eight-Year Follow-Up Study from Prepuberty to Postmenarche. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 44-51.	3.6	154
236	Skeletal Site Selectivity in the Effects of Calcium Supplementation on Areal Bone Mineral Density Gain: A Randomized, Double-Blind, Placebo-Controlled Trial in Prepubertal Boys. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3342-3349.	3.6	101
237	Intrinsic bone tissue properties in adult rat vertebrae: modulation by dietary protein. Bone, 2005, 36, 134-141.	2.9	64
238	Efficacy of risedronate on clinical vertebral fractures within six months. Current Medical Research and Opinion, 2004, 20, 433-439.	1.9	171
239	Dietary Protein and Bone Health. Journal of Bone and Mineral Research, 2004, 19, 527-531.	2.8	115
240	Î²-Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice. Journal of Bone and Mineral Research, 2004, 20, 635-643.	2.8	71
241	The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis. New England Journal of Medicine, 2004, 350, 459-468.	27.0	1,465
242	A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporosis International, 2003, 14, 2-12.	3.1	169
243	Bone strength and its determinants. Osteoporosis International, 2003, 14, 13-18.	3.1	549
244	An Osteoporosis Clinical Pathway for the Medical Management of Patients with Low-Trauma Fracture. Osteoporosis International, 2002, 13, 450-455.	3.1	159
245	Survival and Potential Years of Life Lost After Hip Fracture in Men and Age-matched Women. Osteoporosis International, 2002, 13, 731-737.	3.1	198
246	Two-Year Results of Once-Weekly Administration of Alendronate 70 mg for the Treatment of Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2002, 17, 1988-1996.	2.8	195
247	Dietary Essential Amino Acid Supplements Increase Bone Strength by Influencing Bone Mass and Bone Microarchitecture in Ovariectomized Adult Rats Fed an Isocaloric Low-Protein Diet. Journal of Bone and Mineral Research, 2002, 17, 1264-1272.	2.8	73
248	Protein Intake and Bone Growth. Applied Physiology, Nutrition, and Metabolism, 2001, 26, S153-S166.	1.7	88
249	Gain in bone mineral mass in prepubertal girls 3â€“5 years after discontinuation of calcium supplementation: a follow-up study. Lancet, The, 2001, 358, 1208-1212.	13.7	191
250	Does the Mini Nutritional Assessment predict hospitalization outcomes in older people?. Age and Ageing, 2001, 30, 221-226.	1.6	155
251	Hypoparathyroidism Associated with Aneurysm of the Left Subclavian Artery (Kommerell's) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Research, 2001, 16, 1926-1928.	2.8	4
252	Protein intake and bone disorders in the elderly. Joint Bone Spine, 2001, 68, 383-392.	1.6	65

#	Article	IF	Citations
253	Oligo-amenorrheic long-distance runners may lose more bone in spine than in femur. Medicine and Science in Sports and Exercise, 2001, 33, 15-21.	0.4	59
254	Osteoporosis, genetics and hormones. Journal of Molecular Endocrinology, 2001, 26, 79-94.	2.5	217
255	Osteoporosis in men. Nursing Clinics of North America, 2001, 36, 467-79, ix.	1.5	2
256	Dietary Protein Deficiency Induces Osteoporosis in Aged Male Rats. Journal of Bone and Mineral Research, 2000, 15, 1555-1563.	2.8	95
257	Dietary Protein Restriction Lowers Plasma Insulin-Like Growth Factor I (IGF-I), Impairs Cortical Bone Formation, and Induces Osteoblastic Resistance to IGF-I in Adult Female Rats¹. Endocrinology, 2000, 141, 3149-3155.	2.8	114
258	Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3545-3550.	3.6	39
259	Vitamin D Supplementation during Infancy Is Associated with Higher Bone Mineral Mass in Prepubertal Girls1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4541-4544.	3.6	99
260	Determinants of Peak Bone Mass and Mechanisms of Bone Loss. Osteoporosis International, 1999, 9, S17-S23.	3.1	102
261	Vitamin D Receptor Gene Start Codon Polymorphisms (FokI) and Bone Mineral Density: Interaction with Age, Dietary Calcium, and 3â€²-End Region Polymorphisms. Journal of Bone and Mineral Research, 1998, 13, 925-930.	2.8	142
262	Arginine increases insulin-like growth factor-I production and collagen synthesis in osteoblast-like cells. Bone, 1998, 23, 103-109.	2.9	117
263	Familial Resemblance for Bone Mineral Mass Is Expressed before Puberty1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 358-361.	3.6	224
264	Protein Supplements Increase Serum Insulin-Like Growth Factor-I Levels and Attenuate Proximal Femur Bone Loss in Patients with Recent Hip Fracture. Annals of Internal Medicine, 1998, 128, 801.	3.9	517
265	Asynchrony between the rates of standing height gain and bone mass accumulation during puberty. Osteoporosis International, 1997, 7, 525-532.	3.1	128
266	Protein intake, IGF-1 and osteoporosis. Osteoporosis International, 1997, 7, 36-42.	3.1	84
267	Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial.. Journal of Clinical Investigation, 1997, 99, 1287-1294.	8.2	497
268	Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.. Journal of Clinical Investigation, 1997, 99, 1699-1703.	8.2	287
269	Pregnancy-associated osteoporosis. Lancet, The, 1996, 347, 1274-1276.	13.7	32
270	Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporosis International, 1996, 6, 219-227.	3.1	87

#	Article	IF	Citations
271	A prospective study on socioeconomic aspects of fracture of the proximal femur. Journal of Bone and Mineral Research, 1996, 11, 1935-1942.	2.8	214
272	Histoâ€anatomy of the proximal femur in rats: Impact of ovariectomy on bone mass, structure, and stiffness. The Anatomical Record, 1996, 245, 633-644.	1.8	2
273	Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporosis International, 1995, 5, 39-46.	3.1	71
274	The role of dual energy X-rayabsorptiometry of lumbar spine and proximal femur in the diagnosis and follow-up of osteoporosis. American Journal of Medicine, 1995, 98, 33S-36S.	1.5	92
275	Regulation of parathyroid hormone-related protein production in a human lung squamous cell carcinoma line. Journal of Endocrinology, 1994, 143, 333-341.	2.6	44
276	A thymoma as a cause of true ectopic hyperparathyroidism.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 912-915.	3.6	66
277	Peak bone mass. Osteoporosis International, 1994, 4, S7-S13.	3.1	272
278	Cyclic AMP increases the release of parathyroid hormone-related protein from a lung-cancer cell line. International Journal of Cancer, 1994, 56, 422-426.	5.1	14
279	Hypercalcemia and hyperosteolysis in vitamin D intoxication: Effects of clodronate therapy. Bone, 1994, 15, 193-198.	2.9	77
280	Determination of circulating parathyroid hormone levels and differential diagnosis of hypercalcemia. Nuclear Medicine and Biology, 1994, 21, 337-347.	0.6	2
281	A thymoma as a cause of true ectopic hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 912-915.	3.6	49
282	Relationship between bone mineral density and dietary intakes in the elderly. Osteoporosis International, 1993, 3, 242-248.	3.1	158
283	Alterations of calcium and phosphate metabolism in primary hyperparathyroidism during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 1993, 72, 488-492.	2.8	15
284	Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density. Journal of Bone and Mineral Research, 1993, 8, 1491-1498.	2.8	47
285	Transforming growth factor-beta modulates the parathyroid hormone- related protein-induced responses in renal epithelial cells. Endocrinology, 1993, 133, 145-151.	2.8	6
286	Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects.. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1060-1065.	3.6	661
287	Benefits of oral protein supplementation in elderly patients with fracture of the proximal femur.. Journal of the American College of Nutrition, 1992, 11, 519-525.	1.8	229
288	8 Management of disorders of calcium homoeostasis. Bailliere's Clinical Endocrinology and Metabolism, 1992, 6, 129-142.	1.0	12

#	Article	IF	Citations
289	Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein. Bone, 1992, 13, 321-325.	2.9	15
290	Effect of a single infusion of alendronate in malignant hypercalcaemia: Dose dependency and comparison with clodronate. International Journal of Cancer, 1992, 50, 706-712.	5.1	36
291	Sequential and precise in vivo measurement of bone mineral density in rats using dual-energy x-ray absorptiometry. Journal of Bone and Mineral Research, 1992, 7, 311-316.	2.8	194
292	Actions of parathyroid hormone and parathyroid hormone-related protein. Journal of Endocrinological Investigation, 1992, 15, 51-6.	3.3	5
293	Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone, 1991, 12, 47-56.	2.9	35
294	Critical Years and Stages of Puberty for Spinal and Femoral Bone Mass Accumulation during Adolescence*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 555-563.	3.6	1,006
295	Epidemiology of fractures of the proximal femur in Geneva: Incidence, clinical and social aspects. Osteoporosis International, 1991, 2, 42-47.	3.1	60
296	Stimulation by parathyroid hormone-related protein and transforming growth factor-Î± of phosphate transport in osteoblast-like cells. Journal of Bone and Mineral Research, 1991, 6, 1235-1242.	2.8	20
297	Parathyroid hormone-related protein and hypercalcemia in pancreatic neuro-endocrine tumors. International Journal of Cancer, 1990, 46, 394-398.	5.1	27
298	Effects of lectins and tunicamycin on cAMP response to parathyroid hormone. American Journal of Physiology - Endocrinology and Metabolism, 1989, 256, E80-E86.	3.5	2
299	Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. Journal of Bone and Mineral Research, 1989, 4, 759-765.	2.8	48
300	High extracellular calcium increases the production of a parathyroid hormone-like activity by cultured leydig tumor cells associated with humoral hypercalcemia. Journal of Bone and Mineral Research, 1989, 4, 839-844.	2.8	38
301	Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone, 1988, 9, 123-130.	2.9	115
302	Influence of the Disaccharide Lactitol on Intestinal Absorption and Body Retention of Calcium in Rats. Journal of Nutrition, 1988, 118, 793-795.	2.9	33
303	Effect of pertussis toxin on parathyroid hormone-stimulated cyclic AMP production in cultured kidney cells. Journal of Bone and Mineral Research, 1988, 3, 605-609.	2.8	10
304	Effect of dexamethasone on parathyroid hormone stimulation of cyclic AMP in an opossum kidney cell line. Journal of Cellular Physiology, 1987, 132, 517-523.	4.1	16
305	Calcium absorption in rat large intestine in vivo: availability of dietary calcium. American Journal of Physiology - Renal Physiology, 1986, 251, G14-G18.	3.4	13
306	Increase of adenylate cyclase catalytic-unit activity by dexamethasone in rat osteoblast-like cells. Biochemical Journal, 1986, 237, 447-454.	3.7	31

#	Article	IF	Citations
307	Effect of Hydrochlorothiazide on 1,25-dihydroxyvitamin D3-induced Changes in Calcium Metabolism in Experimental Hypoparathyroidism in Rats. Clinical Science, 1981, 60, 101-107.	4.3	9
308	Effect of thyroparathyroidectomy of calcium metabolism in rats: role of 1,25-dihydroxyvitamin D3.. American Journal of Physiology - Endocrinology and Metabolism, 1977, 233, E160.	3.5	11